{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '7.0', 'DISCONTINUATION OF STUDY TREATMENT AND SUBJECT', 'DISCONTINUATION/WITHDRAWAL', '34', '7.1', 'Pregnancy', '34', '7.2', 'Inadvertent Enrollment', '34', '7.3', 'Adverse Events', '34', '7.4', 'Temporary Discontinuation (Drug Interruption/Holiday)', '34', '7.5', 'Subject Discontinuation/Withdrawal from the Study', '35', '7.6', 'Lost to Follow-Up', '35', '8.0', 'STUDY ASSESSMENTS AND PROCEDURES', '36', '8.1', 'Study Visits', '36', '8.1.1', 'Visit 1 (Screening)', '36', '8.1.2', 'Visit 2 (Baseline)', '37', '8.1.3', 'Visit 3, Visit 4, and Visit 5', '37', '8.1.4', 'Visit 6 (End of Study)', '38', '8.2', 'Efficacy Assessments', '38', '8.2.1', 'Visual Index for Ichthyosis Severity - Scaling', '38', '8.2.2', \"Investigator's Global Assessment\", '39', '8.2.3', 'Itch-Numeric Rating Scale', '40', '8.2.4', 'Percent Body Surface Area with Active Congenital', 'Ichthyosis in the Treatment/Assessment Areas and Over the', 'Entire Body', '40', '8.2.5', 'Dermatology Life Quality Index', '40', '8.3', 'Safety Assessments', '41', '8.3.1', 'Physical Examinations', '41', '8.3.2', 'Vital Signs', '41', '8.3.3', 'Local Skin Reactions', '41', '8.3.4', 'Electrocardiograms', '42', '8.3.5', 'Clinical Safety Laboratory Assessments', '42', '8.4', 'Adverse Events', '42', '8.4.1', 'Time Period and Frequency for Collecting Adverse Event', 'and Serious Adverse Event Information', '43', '8.4.2', 'Method of Detecting Adverse Events and Serious Adverse', 'Events', '43', '8.4.3', 'Follow-Up of Adverse Events and Serious Adverse Events', '43', '8.4.4', 'Regulatory Reporting Requirements for Serious Adverse', 'Events', '44', '8.4.5', 'Pregnancy', '44', '8.4.6', 'Adverse Events of Special Interest', '44', '8.4.7', 'Disease-Related Events and/or Disease-Related Outcomes', 'Not Qualifying as Adverse Events or Serious Adverse Events', '44', '8.5', 'Treatment of Overdose', '45', '8.6', 'Pharmacokinetics', '45', '8.7', 'Pharmacodynamics', '45', '8.8', 'Genetics', '45', '8.9', 'Biomarkers', '46', '4']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '8.10', 'Medical Resource Utilization and Health Economics', '46', '9.0', 'STATISTICAL CONSIDERATIONS', '46', '9.1', 'Statistical Hypotheses', '46', '9.2', 'Sample Size Determination', '46', '9.3', 'Populations for Analyses', '46', '9.4', 'Statistical Analyses', '47', '9.4.1', 'Efficacy Analyses', '48', '9.4.2', 'Safety Analyses', '49', '9.4.3', 'Other Analyses', '50', '9.4.4', 'Missing Data', '50', '9.4.5', 'Extent of Exposure', '51', '9.4.6', 'Dosing Compliance', '51', '9.5', 'Interim Analyses', '51', '9.6', 'Monitoring Committee', '51', '10.0', 'REFERENCES', '52', '11.0', 'APPENDICES', '54', 'Appendix 1', 'Abbreviations', '55', 'Appendix 2', 'Regulatory, Ethical, and Study Oversight Considerations', '57', 'Regulatory and Ethical Considerations', '57', 'Financial Disclosure', '57', 'Insurance', '58', 'Informed Consent Process', '58', 'Data Protection', '58', 'Administrative Structure', '59', 'Medical Monitor', '59', 'Study Site Initiation', '59', 'Dissemination of Clinical Study Data', '59', 'Data Quality Assurance', '59', 'Source Documents', '60', 'Study and Study Center Closure', '60', 'Publication Policy', '61', 'Appendix 3', 'Clinical Laboratory Tests', '62', 'Appendix 4', 'Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '64', 'Appendix 5', 'Excluded Medications/Therapy', '68', 'Appendix 6', 'Contraceptive Guidance and Collection of Pregnancy', 'Information', '69', 'Appendix 7', 'Genetics', '72', 'Appendix 8', 'Signature of Investigator', '73', 'Appendix 9', 'Dermatology Life Quality Index', '74', 'Appendix 10', \"Children's Dermatology Life Quality Index\", '76', 'Appendix 11', 'Itch-Numeric Rating Scale', '77', '5']\n\n###\n\n", "completion": "END"}